Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06592599 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
A Phase 2 study of Nasopharyngeal Carcinoma, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06592599: Recruiting Phase 2 study of Nasopharyngeal Carcinoma, sponsored by Stanford University.
NCT06592599 is a Phase 2 study of Nasopharyngeal Carcinoma that is actively recruiting participants, run by Stanford University. The registered enrollment target is 24 participants, below the 96-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06592599, a Phase 2 study of Nasopharyngeal Carcinoma, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.
Primary Outcome
Induction chemotherapy completion rate, defined as the proportion of patients who complete three cycles of chemoimmunotherapy within 12 weeks of initiation. Completion is defined for induction as receiving all 3 cycles as planned, including protocol specified dose reduction and delays. .
Conditions Studied
Interventions
- DRUG Toripalimab
- RADIATION Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
What NCT06592599 shows while recruiting
NCT06592599 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 96-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Nasopharyngeal Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Toripalimab is the first listed.
NCT06592599 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06592599 about?
NCT06592599 is a clinical study titled "Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)". The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.
What is the current status of trial NCT06592599?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-09-03. Estimated completion is 2029-01.
What conditions does trial NCT06592599 study?
This clinical trial studies the following conditions: Nasopharyngeal Carcinoma.
What interventions are being tested in trial NCT06592599?
The interventions under investigation include: Toripalimab (DRUG), Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation (RADIATION).
Who is sponsoring clinical trial NCT06592599?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06592599 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasopharyngeal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
RECRUITING · NA
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
ACTIVE NOT RECRUITING · Phase 1
-
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
ACTIVE NOT RECRUITING · Phase 1
-
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI